This is from the Street.com's report on GNBT that I found in the research section of TDAmeritrade.
FINANCIAL ANALYSIS GENEREX BIOTECHNOLOGY CORP's gross profit margin for the first quarter of its fiscal year 2010 has significantly decreased when compared to the same period a year ago. Even though sales decreased, the net income has increased. GENEREX BIOTECHNOLOGY CORP is extremely liquid. Currently, the Quick Ratio is 2.93 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased from the same period last year, indicating improving cash flow. At the same time, stockholders' equity ("net worth") has greatly increased by 71.77% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.